Filtered By:
Condition: Heart Attack
Drug: Activase

This page shows you your search results in order of date.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Identification, characterization, and engineering of glycosylation in thrombolyticsa
Biotechnol Adv. 2023 May 12:108174. doi: 10.1016/j.biotechadv.2023.108174. Online ahead of print.ABSTRACTCardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and thrombectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modifica...
Source: Biotechnology Advances - May 14, 2023 Category: Biotechnology Authors: Martin Toul Veronika Slonkova Jan Mican Adam Urminsky Maria Tomkova Erik Sedlak David Bednar Jiri Damborsky Lenka Hernychova Zbynek Prokop Source Type: research

Anterograde Injection of Alteplase Salvages Deep Inferior Epigastric Perforator Flap in Reconstructive Breast Surgery
We report the case of a 43-year-old woman who underwent unilateral breast reconstruction with a DIEP flap at our department. Approximately 12 hours postoperatively, an arterial inflow problem was suspected and revision surgery was performed. Peripheral flap perfusion remained absent without an obvious cause and distal thrombosis was assumed to be present. Therefore, alteplase was gradually injected into the arterial pedicle in the anterograde direction just distal to the anastomosis while clamping the artery proximally. About 3 hours after selective flap thrombolysis, microcirculation of the flap was successfully restored ...
Source: Plastic and Reconstructive Surgery – Global Open - June 1, 2022 Category: Cosmetic Surgery Tags: Breast: Case Report Source Type: research

Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations
CONCLUSION: Current clinical evidence shows that tenecteplase is not inferior to alteplase for the treatment of ischemic stroke and suggests that tenecteplase may have a superior safety profile. Furthermore, tenecteplase also has practical advantages in terms of its administration. This can potentially lead to a decrease in medication errors and improvement in door to thrombolytic time.PMID:35020806 | DOI:10.1093/ajhp/zxac010
Source: American Journal of Health-System Pharmacy : AJHP - January 12, 2022 Category: Drugs & Pharmacology Authors: Kirubel Hailu Chad Cannon Sarah Hayes Source Type: research

Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase
AbstractDesmoteplase is a bat (Desmodus rotundus) saliva-derived fibrinolytic enzyme resembling a urokinase and tissue plasminogen activator. It is highly dependent on fibrin and has some neuroprotective attributes. Intravenous administration of desmoteplase is safe and well tolerated in healthy subjects. Plasma fibrinolytic activity is linearly related to its blood concentration, its terminal elimination half-life ranges from 3.8 to 4.92  h (50 vs. 90 μg/kg dose). Administration of desmoteplase leads to transitory derangement of fibrinogen, D-dimer, alpha2-antiplasmin, and plasmin and antiplasmin complex which normaliz...
Source: European Journal of Drug Metabolism and Pharmacokinetics - December 11, 2021 Category: Drugs & Pharmacology Source Type: research

Acute Ischemic Stroke Associated with Myocardial Infarction: Challenges and Management
Semin Neurol DOI: 10.1055/s-0041-1726333Acute ischemic stroke (AIS) and acute myocardial infarction (AMI) may co-occur simultaneously or in close temporal succession, with occurrence of one ischemic vascular event increasing a patient's risk for the other. Both employ time-sensitive treatments, and both benefit from expert consultation. Patients are at increased risk of stroke for up to 3 months following AMI, and aggressive treatment of AMI, including use of reperfusion therapy, decreases the risk of AIS. For patients presenting with AIS in the setting of a recent MI, treatment with alteplase, an intravenous tissue plasmi...
Source: Seminars in Neurology - April 13, 2021 Category: Neurology Authors: Boyanpally, Anusha Cutting, Shawna Furie, Karen Tags: Review Article Source Type: research

Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Abstract Vascular occlusion is one of the major causes of mortality and morbidity. Blood vessel blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep venous thrombosis, peripheral occlusive disease, and pulmonary embolism. Thrombolytic therapy currently aims to rectify this through the administration of recombinant tissue plasminogen activator. Research is underway to design an ideal thrombolytic drug with the lowest risk. Despite the potent clot lysis achievable using approved thrombolytic drugs such as alteplase, reteplase, streptokinase, tenecteplase, and some other fibrinoly...
Source: Molecular Biology Reports - October 31, 2019 Category: Molecular Biology Authors: Nedaeinia R, Faraji H, Javanmard SH, Ferns GA, Ghayour-Mobarhan M, Goli M, Mashkani B, Nedaeinia M, Haghighi MHH, Ranjbar M Tags: Mol Biol Rep Source Type: research

Thrombolysis with Reteplase in Acute Pulmonary Embolism
ConclusionsDouble bolus reteplase given with heparin is effective in the treatment of high, intermediate risk pulmonary embolism with minimal risk of bleeding.
Source: Indian Heart Journal - September 22, 2019 Category: Cardiology Source Type: research

Choosing the Correct “-ase” in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase
Alteplase is a tissue plasminogen activator approved for treating acute ischemic stroke (AIS), acute myocardial infarction (AMI), and acute massive pulmonary embolism. Two additional tissue plasminogen activators, tenecteplase and reteplase, are also approved for AMI treatment. However, neither tenecteplase nor reteplase is approved for AIS treatment. The U.S. Food and Drug Administration has received reports of accidental administration of tenecteplase or reteplase instead of alteplase in patients with AIS, which can lead to potential overdose. Primary factors contributing to medication errors include use of the abbreviat...
Source: Advanced Emergency Nursing Journal - July 1, 2019 Category: Emergency Medicine Tags: PROCEDURAL COLUMN Source Type: research

Making a case for the right "-ase" in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
Authors: Wyatt Chester K, Corrigan M, Schoeffler JM, Shah M, Toy F, Purdon B, Dillon GM Abstract INTRODUCTION: Alteplase, reteplase, and tenecteplase are tissue plasminogen activators (TPA) approved for the management of acute myocardial infarction. Only alteplase is also approved for the treatment of acute ischemic stroke (AIS). The US Food and Drug Administration has received reports of accidental administration of tenecteplase or reteplase instead of alteplase in patients with AIS, which can result in failure to treat patients with the intended agent and lead to potential overdose. Areas covered: This review com...
Source: Expert Opinion on Drug Safety - February 5, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Think Twice Before Using This Abbreviation
A patient with slurred speech and a facial droop presented to an emergency department late in the evening on a weekend. After rapid assessment, a probable diagnosis of stroke was made and alteplase was quickly prescribed. In this emergency department, this drug was commonly referred to as “t-PA.” Approaching the automated dispensing cabinet (ADC), the nurse typed “t” and “tenecteplase” appeared on the selection screen; he selected this drug and removed it from the cabinet. The Pharmacy and Therapeutics Committee of this hospital approved the use of tenecteplase (TNKase) f or ST segment elevation myocardial infa...
Source: Journal of Emergency Nursing: JEN - January 1, 2019 Category: Nursing Authors: Susan F. Paparella Tags: Danger Zone Source Type: research

Myocardial Infarction Following Intravenous Thrombolysis for Acute Ischemic Stroke: Case Report and Literature Review
We describe a case of early anterior myocardial infarction during intravenous thrombolysis for stroke and review the current literature.
Source: Journal of Stroke and Cerebrovascular Diseases - April 20, 2017 Category: Neurology Authors: Marina Mannino, Salvatore Asciutto, Valeria Terruso, Matilde Gammino, Melchiorre Gilberto Cellura, Serena Monaco Tags: Case Studies Source Type: research